Skip to main content

Table 1 Clinical, imaging, and laboratory findings of the patients selected for the preparation of CSF seeds (CTR CSF: control patients’ group, AD CSF: Alzheimer’s disease group). Bold letters indicate pathological values of CSF tau, p-tau or Aβ. NIA-AA criteria: National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Criteria abbreviation: BP = “Biomarker probability of AD etiology” [2, 25]

From: Cerebrospinal fluid from Alzheimer’s disease patients promotes tau aggregation in transgenic mice

patient number

group

diagnosis NIA-AA criteria

alternative clinical diagnosis

age

MMS

Brain MRI

SPECT

CSF tau (pg/ml)

CSF p-tau (pg/ml)

CSF Aβ (pg/ml)

1

CTR

Dementia unlikely to be due to AD

vascular encephalopathy

80

26

vascular encephalopathy

no signs of AD or FTD, compatible with vascular encephalopathy

500

78

544

2

CTR

Dementia unlikely to be due to AD

neurocognitive deficits associated with progressive pancreas carcinoma and tumorectomy

73

25

mild vascular microangiopathy

206

50

580

3

CTR

MCI - unlikely to be due to AD

early Wernicke–Korsakoff syndrome

61

30

compatible with Wernicke-Korsakoff syndrome

compatible with Wernicke-Korsakoff syndrome

162

43

928

4

CTR

MCI - unlikely to be due to AD

depression

57

28

normal

360

53

1133

1

AD

Probable AD with high BP

73

25

hippocampal atrophy, no vascular lesions

840

105

366

2

AD

Probable AD with high BP

61

24

temporal brain atrophy

Left parietal decreased glucose metabolism compatible with early AD

500

92

318

3

AD

MCI - core clinical data

79

28

mild hippocampal atrophy

759

119

516

4

AD

Probable AD with intermediate BP

71

23

left hippocampal atrophy, microangiopathy

308

77

240

5

AD

Probable AD with intermediate BP

74

21

hippocampal and global brain atrophy, mild microangiopathy

238

32

402